Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023)
Gain Therapeutics (GANX) posted EBITDA Margin of 9477.68% for Q1 2023, down 74.13% on a QoQ basis from 5442.98% in Q2 2022, and down 217093.0% year-over-year from N/an in Q1 2022.
Powered by 
Analysis
Gain Therapeutics (GANX) EBITDA Margin (2020 - 2023) Analysis & Trends
Gain Therapeutics has reported EBITDA Margin for 4 years, with the latest figure at 9477.68% in Q1 2023.
- On a quarterly basis, EBITDA Margin fell 217093.0% year-over-year to 9477.68% in Q1 2023; TTM through Dec 2023 was 40328.26%, a 2764016.0% decrease from a year earlier, with the FY2023 full-year figure at 40328.26%, down 2764016.0% from the prior year.
- EBITDA Margin was 9477.68% for Q1 2023 at Gain Therapeutics, down from 5442.98% in the prior quarter.
- The five-year high for EBITDA Margin was 3941.29% in Q2 2021, with the low at 46819.42% in Q1 2021.
- Average EBITDA Margin over 4 years is 13028.23%, with a median of 8355.01% recorded in 2020.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin sank 3914281 bps in 2021, then jumped 3951266 bps in 2022.
- Over 4 years, EBITDA Margin stood at 17678.47% in 2020, then surged by 58 bps to 7426.33% in 2021, then gained by 27 bps to 5442.98% in 2022, then tumbled by 74 bps to 9477.68% in 2023.
- The last three EBITDA Margin figures came in at 9477.68% (Q1 2023), 5442.98% (Q2 2022), and 7306.75% (Q1 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Gain Therapeutics | 73.54 Mn | 73.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -9,477.68% |
| Jun 30, 2022 | -5,442.98% |
| Mar 31, 2022 | -7,306.75% |
| Dec 31, 2021 | -7,426.33% |
| Sep 30, 2021 | -16,953.46% |
| Jun 30, 2021 | -3,941.29% |
| Mar 31, 2021 | -46,819.42% |
| Dec 31, 2020 | -17,678.47% |
| Sep 30, 2020 | -12,232.51% |
| Jun 30, 2020 | -8,355.01% |
| Mar 31, 2020 | -7,676.61% |